Adenocarcinoma of prostate
Item
histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Neoplasm Metastasis Evidence of
Item
evidence of metastatic disease
boolean
C0027627 (UMLS CUI [1,1])
C0332120 (UMLS CUI [1,2])
Antiandrogen therapy | Disease Progression
Item
disease progression following androgen deprivation therapy
boolean
C0279492 (UMLS CUI [1])
C0242656 (UMLS CUI [2])
Chemotherapy docetaxel Based | Disease Progression
Item
disease progression despite docetaxel-based chemotherapy
boolean
C0392920 (UMLS CUI [1,1])
C0246415 (UMLS CUI [1,2])
C1705938 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2])
Serum testosterone measurement | Male Castration | Antiandrogen therapy | Luteinizing Hormone-releasing Hormone Agonist | Orchiectomy
Item
serum testosterone levels less than 50ng/ml (unless surgically castrated). patients must continue androgen deprivation with a luteinizing hormone-releasing hormone (lhrh) analogue if they have not undergone orchiectomy.
boolean
C0428413 (UMLS CUI [1])
C0007347 (UMLS CUI [2])
C0279492 (UMLS CUI [3])
C1518041 (UMLS CUI [4])
C0029189 (UMLS CUI [5])
Androgen Antagonists
Item
no use of antiandrogens for at least 4 weeks
boolean
C0002842 (UMLS CUI [1])
Cancer and Leukemia Group B performance status
Item
cancer and leukemia group b (calgb) performance status less than or equal to 2
boolean
C1516238 (UMLS CUI [1,1])
C1518965 (UMLS CUI [1,2])
White Blood Cell Count procedure | Platelet Count measurement | Creatinine measurement, serum | Aspartate aminotransferase measurement
Item
acceptable white blood cell (wbc), platelets, creatinine and ast counts
boolean
C0023508 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0201899 (UMLS CUI [4])
Peripheral Neuropathy Significant CTCAE Grades
Item
significant peripheral neuropathy defined as grade 2 or higher
boolean
C0031117 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,3])
External Beam Radiation Therapy Complete | radiopharmaceutical therapy Complete | Strontium | Samarium
Item
within 4 weeks since completing external beam radiotherapy or 8 weeks since completing radiopharmaceutical therapy (strontium, samarium)
boolean
C1517033 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C2094663 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C0038467 (UMLS CUI [3])
C0036147 (UMLS CUI [4])
Chemotherapy Platinum-Based Hormone refractory prostate cancer | Cisplatin | Carboplatin
Item
prior platinum-based chemotherapy (cisplatin or carboplatin) for hormone- refractory prostate cancer
boolean
C0392920 (UMLS CUI [1,1])
C1514162 (UMLS CUI [1,2])
C1328504 (UMLS CUI [1,3])
C0008838 (UMLS CUI [2])
C0079083 (UMLS CUI [3])
Chemotherapy | Investigational New Drugs | systemic steroids
Item
concomitant chemotherapy, investigational agents or systemic steroids
boolean
C0392920 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C2825233 (UMLS CUI [3])